Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

COLBY PHARMACEUTICAL CO

UEI: E485BYCZNN71CAGE: 47VE9

COLBY PHARMACEUTICAL CO is a federal contractor, registered under UEI E485BYCZNN71 and CAGE code 47VE9. It has been awarded $8,401,407 across 4 federal contracts. Primary work spans Unknown NAICS and Research and Development in Biotechnology. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Websitewww.colbypharmaceuticals.com

Address123 Main St, City, ST 12345

Registration

UEI Code

E485BYCZNN71

CAGE Code

47VE9

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit Organization

NAICS Codes

541714Research and Development in Biotechnology (except Nanobiotechnology)(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

COLBY PHARMACEUTICAL CO operates as a specialized research and development contractor within the life sciences sector, leveraging its expertise in pharmaceutical sciences to support federal health and biomedical initiatives. Based on its NAICS classification of 541714, the company engages in scienti...

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Department Of Health And Human Services$8.4M100%

Awards by NAICS

- Unknown NAICS$7.2M85.9%

541711 - Research and Development in Biotechnology$1.2M14.1%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in COLBY PHARMACEUTICAL CO's top NAICS codes and agencies

DDDPlus Software Licensing and SupportThe contract entails the provision of five individual Standard licenses for DDDPlus software, covering full delivery, installation, and compatibility testing to ensure seamless integration with existing systems. License administration will be maintained throughout a four-year term, including ongoing support and compliance management. The work is performance-based with the place of performance located in Silver Spring, Maryland, under a subcontract structure, and falls under the NAICS code 511210 for software publishing. The Department of Health and Human Services is the contracting organization, with a response deadline set for August 14, 2026, and the solicitation was posted on August 4, 2026. All activities must align with federal procurement standards and deliverables must meet technical and operational requirements specified in the agreement.

Department Of Health And Human Services

POSTED

DEADLINE

GastroPlus Software Licensing and SupportThe contract awards the supply and ongoing support of 20 Standard licenses for GastroPlus software over a four-year period, encompassing full delivery, installation, and verification of compatibility with FDA systems. The provider is responsible for ensuring seamless integration into existing infrastructure and managing all aspects of license administration throughout the term. Performance is required to occur at the designated location in Silver Spring, Maryland, with the work falling under NAICS code 511210 for software publishing. The opportunity was posted on August 4, 2026, and responses are due by August 14, 2026, with the contracting entity being the Department of Health and Human Services. This subcontract supports critical regulatory and scientific operations that rely on GastroPlus for pharmacokinetic and pharmacodynamic modeling within federal health and safety contexts.

Department Of Health And Human Services

POSTED

DEADLINE

Notice of Sole Source: GastroPlus PBPK and PBBM modeling platform subscription

Solicitation # 7571TE26Q00153

The U.S. Food and Drug Administration, through the Department of Health and Human Services, intends to sole-source a firm fixed-price contract to Simulations Plus Inc. for twenty GastroPlus and five DDDPlus software licenses, used for physiologically based pharmacokinetic and physiologically based biopharmaceutics modeling in support of generic drug research. The contract spans a base year from September 1, 2026, to August 31, 2027, with up to three one-year option periods extending through August 31, 2030. Performance will occur at the FDA’s White Oak campus in Silver Spring, Maryland. The acquisition is conducted under RFO 12, allowing for non-competitive procurement of commercial products, and no set-aside applies. Responses are due by August 14, 2026, and any interested party may submit a capability statement to demonstrate their ability to supply the exact software licenses as the original equipment manufacturer or authorized reseller, which the government will review solely to determine whether competitive procurement is warranted. The contract requires the vendor to provide standard individual licenses, with no auto-renewals permitted unless explicitly authorized. Acceptance of deliverables will be conducted by the Contracting Officer’s Representative within 30 working days of delivery, verifying software functionality, compatibility with FDA systems, and compliance with technical requirements. Invoicing must be submitted electronically through the Treasury’s Invoice Processing Platform, and all invoices must include detailed supporting documentation for labor, materials, and costs. The government retains the right to reject nonconforming deliveries and will not pay for services that fail to meet agreed standards. Clauses from the FAR and HHSAR govern payment, representation, whistleblower rights, anti-lobbying, accessibility, and dispute resolution, with federal regulations taking precedence over any vendor terms. The Contracting Officer and Contract Specialist are the primary points of contact, and all vendors must be actively registered in SAM at the time of submission.

Department Of Health And Human Services

POSTED

DEADLINE

In Vitro ADMET AssaysThe contract titled In Vitro ADMET Assays calls for the performance of high-throughput in vitro screening focused on metabolic stability, hepatotoxicity, CYP450 enzyme interactions, and cellular permeability to support early-stage drug development. These assays are critical for evaluating the absorption, distribution, metabolism, excretion, and toxicity profiles of potential therapeutic candidates, enabling informed decisions before advancing compounds into costly clinical stages. The work will be conducted to meet the specific needs of the National Institutes of Health NIDA under the Department of Health and Human Services, with performance expected to occur in Bethesda. This is a subcontract opportunity under NAICS code 541711, which classifies it as research and development in the physical, engineering, and life sciences. The solicitation was posted on August 3, 2026, with a response deadline of August 18, 2026, at 7:00 PM Eastern Time. There is no set-aside classification specified, and no point of contact or detailed office address is provided in the data. Interested parties must submit their proposals before the deadline to be considered for award, with the expectation that the selected contractor will deliver reliable, scalable, and scientifically rigorous ADMET data to guide NIDA’s research initiatives in drug development.

National Institutes Of Health Nida

POSTED

DEADLINE

Genotoxicity and Carcinogenicity TestingThe contract seeks to perform in vitro and in vivo assays to assess the mutagenic and carcinogenic risks of drug candidates, ensuring compliance with regulatory safety standards for pharmaceutical development. The work is critical for identifying potential genetic toxicity and cancer-causing properties early in the drug evaluation process to support regulatory submissions and public health safeguards. The solicitation is issued as a subcontract under the National Institutes of Health NIDA, part of the Department of Health and Human Services, with performance expected to take place in Bethesda. It falls under the NAICS code 541711 for research and development in the physical, engineering, and life sciences. The proposal must be submitted by August 18, 2026, with the opportunity posted on August 3, 2026. No set-aside provisions are specified, and the contract is open to qualified subcontractors with the technical capacity to deliver high-quality genotoxicity and carcinogenicity testing services.

National Institutes Of Health Nida

POSTED

DEADLINE

Safety Pharmacology (CNS, Cardiovascular, Pulmonary)The contract requires comprehensive safety pharmacology studies to evaluate adverse effects on the central nervous system, cardiovascular system, and pulmonary function, ensuring alignment with ICH safety guidelines. The work will involve detailed pharmacodynamic assessments to identify and characterize potential risks to major organ systems during early drug development, with a focus on identifying safety signals that could impact clinical translation. This subcontract, issued by the National Institutes of Health’s NIDA under the Department of Health and Human Services, is set to be performed in Bethesda and has a response deadline of August 18, 2026. The effort is classified under NAICS code 541711, indicating it pertains to research and development in the life sciences, and is aimed at supporting regulatory-compliant preclinical safety evaluations essential for pharmaceutical advancement.

National Institutes Of Health Nida

POSTED

DEADLINE

Toxicity Testing (Acute, Subacute, Subchronic, Chronic)The contract requires the performance of comprehensive toxicity testing in both rodent and non-rodent models to assess organ toxicity and establish safety margins for submission to regulatory authorities as part of an Investigational New Drug application. The scope includes acute, subacute, subchronic, and chronic studies designed to evaluate the potential adverse effects of pharmaceutical compounds across a range of exposure durations and dosages. The work must meet rigorous scientific standards to support regulatory filings and ensure the safety profile of investigational drugs is adequately characterized prior to human trials. This subcontract is issued under the National Institutes of Health, National Institute on Drug Abuse, within the Department of Health and Human Services, with the performance location specified as Bethesda. The North American Industry Classification System code 541711 identifies the work as research and development in the life sciences. The solicitation was posted on August 3, 2026, with a mandatory response deadline of August 18, 2026, at 7:00 PM. No set-aside provisions are specified, and the contract opportunity is open to eligible contractors capable of executing preclinical toxicology studies to support IND submissions.

National Institutes Of Health Nida

POSTED

DEADLINE

In Vivo Pharmacokinetic StudiesThe contract seeks to perform in vivo pharmacokinetic studies to assess the absorption, distribution, metabolism, and excretion of a drug candidate in both rodent and non-rodent species across multiple administration routes, with the goal of generating data to support an Investigational New Drug application. These studies will evaluate drug exposure over time to establish pharmacokinetic profiles critical for regulatory submission, requiring rigorous experimental design, appropriate species selection, and adherence to good laboratory practices. All work must be completed to ensure high-quality, reproducible results that meet FDA expectations for preclinical development. The solicitation is classified as a subcontract under NAICS code 541711, issued by the National Institutes of Health through the National Institute on Drug Abuse, part of the Department of Health and Human Services. Performance is expected to take place in Bethesda, and interested parties must submit their responses no later than August 18, 2026, at 7:00 PM. The opportunity was posted on August 3, 2026, and is open for competitive bidding with no specific set-aside designation. The contract does not provide a point of contact, and all inquiries must be directed through the official SAM.gov portal linked in the posting.

National Institutes Of Health Nida

POSTED

DEADLINE

Unable to Decompose Subcontract OpportunitiesDue to a system error, the prime contract details necessary to identify or structure subcontract opportunities could not be retrieved, rendering all subcontracting analysis unavailable at this time. The solicitation is designated as a subcontract under the Department of Health and Human Services, with a posted date of August 3, 2026, and a response deadline of August 18, 2026. The place of performance is listed as Bethesda, Maryland, with a zip code of 20892, though no specific office address, point of contact, or set-aside information is provided. The NAICS code is marked as NA, and the agency and organizational designations are identical, indicating an internal system limitation. Despite the absence of actionable data for suppliers, the opportunity remains live in the system with a public view link available for reference.

Department Of Health And Human Services

POSTED

DEADLINE

Antioxidant Therapy for Smith-Lemli-Opitz Syndrone

Solicitation # NICHD-08610

The contract pertains to the development and implementation of antioxidant therapy for Smith-Lemli-Opitz Syndrome, a rare genetic disorder characterized by multiple congenital anomalies and metabolic dysfunction. The solicitation, issued under NICHD-08610 by the Department of Health and Human Services through its National Institutes of Health, invites proposals aimed at advancing targeted antioxidant interventions to mitigate the pathological effects of the condition. The opportunity was posted on August 3, 2026, with responses due by August 18, 2026, at 2:00 PM Eastern Time. The work is expected to be performed in Bethesda, Maryland, consistent with the research infrastructure of the NIH campus. All proposals must be submitted through the SAM.gov portal and should address scientific rigor, feasibility, and potential clinical impact. The primary point of contact for inquiries is Niamh Cawley, with Chung Huang as the secondary contact, both reachable via NIH email addresses. The contracting activity falls under the Department of Health and Human Services with no set-aside provisions specified, and no NAICS code is assigned, indicating flexibility in contractor categorization. Interested parties should ensure adherence to deadlines and submission requirements outlined on the official UI link linked in the posting.

Department Of Health And Human Services

POSTED

DEADLINE

Influenza Vaccine Clinical Trial ManagementThe contract pertains to the design and management of Phase I–III clinical trials for influenza vaccines, encompassing all critical aspects from protocol development and site selection to patient recruitment and regulatory reporting to the FDA. The work requires specialized expertise in infectious disease trials, with a focus on ensuring compliance with regulatory standards and timely submission of clinical data. The performance location is in Washington, DC, with a zip code of 20024, indicating the primary operational base for trial oversight and coordination. This is a subcontract under the Department of Health and Human Services, specifically managed by Barda – ASPR / DAAPPO / Barda DCMA, with a NAICS code of 541711 indicating scientific research and development services. The opportunity was posted on July 30, 2026, with a response deadline of August 15, 2026, at 9:00 PM ET. While no set-aside type or point of contact is specified, the emphasis on end-to-end clinical trial management suggests the subcontractor must possess a proven track record in vaccine development, regulatory engagement, and multi-site trial execution under federal health security initiatives.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Notice of Intent / Sole Source Solid Waste

Solicitation # 75H71026Q00223

The Navajo Area Indian Health Service, Shiprock Service Unit, intends to award a sole-source, firm-fixed-price contract to Navajo Sanitation for solid waste collection services at the Dzilth-Na-O-Dith-Hle Health Center in Bloomfield, New Mexico, with performance beginning September 1, 2026, and ending August 31, 2027. The procurement is justified under unusual and compelling urgency due to the contractor’s unique, uninterrupted history of providing essential waste management services at the facility, ensuring continuity of operations critical to patient care. The North American Industry Classification System code is 562111, with a small business size standard of $47 million in annual revenue. No competitive solicitation will be issued unless a respondent submits clear and convincing evidence that competition would benefit the government. Responses must be submitted in writing as a capability statement by August 17, 2026, at 10:00 a.m. MST, and must not include proprietary, classified, confidential, or sensitive information. The government is not obligated to respond to or acknowledge submissions, and failure to receive affirmative responses will result in contract award without further notice. All information provided may be used in future solicitations if competition is pursued, and any resulting solicitation will be publicly announced on SAM.gov. The point of contact for inquiries is Ken Parrish, Purchasing Agent, reachable at ken.parrish@ihs.gov.

Department Of Health And Human Services

POSTED

DEADLINE

Clinical Trial Design and Efficacy Data GenerationThe contract calls for the design and execution of clinical trials aimed at evaluating the safety, wound closure, infection control, and functional regeneration outcomes of medical interventions in patients with burn and trauma injuries. The work requires rigorous scientific methodology to generate robust efficacy data that supports regulatory and clinical adoption, with a focus on measurable endpoints related to tissue recovery and patient outcomes. The trials must be conducted in accordance with established clinical standards and are intended to provide evidence of therapeutic effectiveness under real-world conditions. This is a subcontract under the Aspr Administration for Strategic Preparedness and Response, part of the Department of Health and Human Services, with a solicitation posted on July 28, 2026, and a response deadline of August 28, 2026. The work is classified under NAICS code 541711, indicating research and development in the life sciences. The performance location is designated with a zip code of 77416, though no specific city or state is provided, and no point of contact details are listed. The contract does not include a set-aside designation, and all eligible entities may respond, with emphasis placed on technical capability, trial design expertise, and experience in trauma and burn clinical research.

Aspr Administration For Strategic Preparedness And Response

POSTED

DEADLINE

Induced Pluripotent Stem Cell (iPSC) Reprogramming ServicesThe contract entails the reprogramming of human articular chondrocytes and bone marrow cells into induced pluripotent stem cells using Sendai virus technology, with full support for culture expansion and cryopreservation of the resulting iPSCs. This subcontract is part of a research initiative led by the Department of Veterans Affairs through Rpo East, focused on advancing regenerative medicine techniques through advanced cellular reprogramming methods. The work requires precise adherence to protocols ensuring high efficiency, safety, and scalability of iPSC generation while maintaining cell viability and pluripotency throughout the process. The solicitation is open for responses until August 6, 2026, and falls under NAICS code 541711, indicating it is for research and development in the biological sciences. The agreement is structured as a subcontract, suggesting it will be awarded to a specialized contractor with expertise in stem cell biology and virology-based reprogramming. Performance is expected to meet rigorous quality standards for cellular products intended for potential therapeutic or diagnostic applications, with an emphasis on reproducibility and documentation. All deliverables must include verified iPSC lines archived through cryopreservation, ready for downstream use in future studies or clinical translation.

Rpo East (36C24E)

POSTED

DEADLINE

in about 14 hours

Emerging Animal & Zoonotic Disease Diagnostics Research

Sci Technology Acq Division

POSTED

DEADLINE

OHS Region 11 Training and Technical Assistance Network

Solicitation # 7571MN26C00013

The Department of the Interior’s existing contract with ICF Incorporated, LLC, numbered 140D0425C0027, has been administratively transferred to the Department of Health and Human Services under a new task order, 7571MN26C00013, effective July 1, 2026. This transfer is purely administrative and does not alter the original contract’s scope of work, deliverables, ultimate value, or period of performance. The work continues under the same terms and conditions, now managed by HHS to support the OHS Region 11 Training and Technical Assistance Network, with performance based in Reston, Virginia, and administrative oversight from Washington, DC. The contract, classified under NAICS code 541611, remains unrestricted with no set-aside requirements and is fully maintained under the original contractor’s responsibility. Point of contact for inquiries includes Carla Carter and Hamed Hassanzadeh Makou at HHS.

Department Of Health And Human Services

POSTED

about 1 month ago

DEADLINE

Preclinical Animal Studies for Neurofibromatosis ResearchThe contract seeks to conduct preclinical in vivo studies using genetically engineered mouse models or alternative animal models of neurofibromatosis to assess the efficacy of therapeutic interventions, track tumor progression, and investigate underlying biological mechanisms. The work requires advanced expertise in animal modeling, tumor biology, and preclinical drug evaluation, with a focus on generating robust, reproducible data to support future clinical translation. All studies must be conducted in accordance with established ethical and scientific standards for animal research, with detailed documentation of methodologies, outcomes, and adverse events. This subcontract is issued under the Defense Health Agency Contracting Activity and falls under NAICS code 541711, indicating it supports research and development in the physical, engineering, and life sciences. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is open to qualified entities capable of executing complex preclinical studies. While the place of performance and point of contact details are unspecified, successful proposers must demonstrate capacity to manage animal facilities, comply with regulatory requirements, and deliver high-quality, timely results in support of neurofibromatosis research objectives under the Department of Defense.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

in about 2 months

Collaborative Biomedical Research ExecutionThis contract enables a collaborative biomedical research effort focused on neurofibromatosis, requiring coordinated hypothesis-driven investigations led by an Initiating Principal Investigator and a Partnering Principal Investigator. The work encompasses the design of experiments, generation of empirical data, and rigorous milestone-based progress reporting to ensure scientific rigor and accountability. The project is structured as a subcontract under the Defense Health Agency Contracting Activity, falling under the NAICS code for research and development in the physical, engineering, and life sciences, and is intended to advance understanding of neurofibromatosis through integrated scientific contributions. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is managed by the Department of Defense through its health research infrastructure. While no set-aside provisions or specific location details are provided, the emphasis is firmly on outcome-driven research with clearly defined deliverables tied to research milestones. The effort requires close alignment between the two principal investigators to ensure cohesive experimental planning, data integrity, and timely reporting, reflecting a strategic investment in translational medical science with potential implications for defense-relevant health conditions.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

in about 2 months